Tapotoclax 是一种针对诱导性髓系白血病细胞分化蛋白 MCL-1 的高效抑制剂 (Ki=0.13 nM)，具备潜在的促凋亡和抗肿瘤活性。给药后，Tapotoclax 与 MCL-1 结合，从而抑制其功能。这一过程阻止了 MCL-1 与 Bcl-2 类蛋白 11 (BCL2L11；BIM) 的复合物形成，并进一步触发肿瘤细胞凋亡。 Tapotoclax is a potent inhibitor (Ki=0.13 nM) of the inducible myeloid leukemia cell differentiation protein MCL-1, with potential pro-apoptotic and anti-tumor activity. Upon administration, Tapotoclax binds to MCL-1, thereby inhibiting its function. This process prevents the formation of a complex between MCL-1 and Bcl-2-like protein 11 (BCL2L11; BIM) and further triggers apoptosis in tumor cells.